Asset Details
Do you wish to reserve the book?
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy
Do you wish to request the book?
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy
2024
Overview
Standard testing for disease evaluation in B-cell acute lymphoblastic leukemia (B-ALL) includes examination of the bone marrow and cerebrospinal fluid. Radiographic or functional imaging are indicated when clinical signs of non-CNS extramedullary disease are present but are not standard in the relapsed/refractory setting. We describe two cases of patients with relapsed/refractory B-ALL with prior exposure to blinatumomab and/or inotuzumab ozogamicin presenting for CAR-T cell treatment. Both patients were thought to only have minimal residual disease (MRD) at the pre-CAR disease assessment, with MRD of 6,648 (0.66%) and 100 (0.01%) cells per million cells, respectively, as measured by next-generation sequencing (NGS) in their bone marrows. Both patients for distinct reasons unrelated to non-CNS extra-medullary (EM) symptoms had PET-MRIs prior to lymphodepletion and CAR T cell infusion. In both cases patients were found to have significant bulky subclinical EM disease that required changes in clinical management. In the newly-emergent era of antigen-targeted immunotherapy, it is foundational that incidence and relapse patterns following targeted therapy are well-understood. Herein we contribute to a growing body of literature addressing this fundamental clinical gap and highlight a future role for formal prospective imaging studies to better establish response, toxicity and relapse patterns following CAR-T cell therapy in EM B-ALL.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Adult
/ Antibodies, Bispecific - therapeutic use
/ Antigens
/ B-ALL
/ CAR (chimeric antigen receptor) T cells
/ extramedullary acute lymphoblastic leukemia
/ Female
/ Humans
/ Immunotherapy, Adoptive - adverse effects
/ Leukemia
/ Male
/ Patients
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy
/ Toxicity
